H. Lundbeck AS (FRA:LDBA) ROCE %: 19.92% (As of Mar. 2026)


FRA:LDBA H. Lundbeck AS FRA:LDBA
81 GF Score
Price €5.93
GF Value €6.14
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS ROCE %?

H. Lundbeck AS FRA:LDBA +3.13% 81 ROCE % is 19.92% as of Mar. 2026. GuruFocus rates FRA:LDBA with a GF Score™ of 81/100 and a GF Value™ of €6.14 (Fairly Valued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. H. Lundbeck AS's annualized ROCE % for the quarter that ended in Mar. 2026 was 19.92%.

H. Lundbeck AS  (FRA:LDBA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

H. Lundbeck AS ROCE % Related Terms

H. Lundbeck AS ROCE % Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS ROCE % Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.69 9.35 10.38 9.76 10.83

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.86 13.83 14.76 0.93 19.92
FRA:LDBA
81GF Score
H. Lundbeck AS FRA:LDBA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS ROCE % Calculation

H. Lundbeck AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=669.581/( ( (7731.61 - 1150.489) + (6969.478 - 1185.323) )/ 2 )
=669.581/( (6581.121+5784.155)/ 2 )
=669.581/6182.638
=10.83 %

H. Lundbeck AS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1153.28/( ( (6969.478 - 1185.323) + (6997.947 - 1202.916) )/ 2 )
=1153.28/( ( 5784.155 + 5795.031 )/ 2 )
=1153.28/5789.593
=19.92 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 19.92% mean?
H. Lundbeck AS (FRA:LDBA) has a ROCE % of 19.92% as of Mar. 2026.
Is H. Lundbeck AS's ROCE % too high?
H. Lundbeck AS's current ROCE % is 19.92%. The Drug Manufacturers industry median ROCE % is 7.03. H. Lundbeck AS's value of 19.92% is 183.4% above this industry median. Overall, H. Lundbeck AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's ROCE % compare to ZTS and UTHR?
H. Lundbeck AS's ROCE % of 19.92% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. H. Lundbeck AS's value of 19.92% is 183.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current ROCE % of 19.92% is 183.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current ROCE % is 19.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.14, compared to a current price of €5.93 — trading 3.5% below its estimated fair value. The current ROCE % is 19.92% and 183.4% above the Drug Manufacturers industry median of 7.03. H. Lundbeck AS's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current ROCE % is 19.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.93 is trading 3.5% below its estimated GF Value™ of €6.14. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for FRA:LDBA:

  • ROCE %: 19.92%
  • GF Value™: €6.14 vs. price of €5.93 (3.5% below fair value)
  • GF Score™: 81/100 with 3 warning signs
  • Industry Position: 183.4% above the Drug Manufacturers median

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score

Get the complete analysis for FRA:LDBA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.93
Price
€6.14
GF Value